Prasugrel in NSTEMI
نویسندگان
چکیده
منابع مشابه
Approach to STEMI and NSTEMI.
Acute coronary syndrome (ACS) refers to any constellation of clinical symptoms that are compatible with acute myocardial ischemia. ACS is divided into ST- elevated myocardial infarction (STEMI), non-ST elevated myocardial infarction (NSTEMI), and unstable angina (UA). STEMI results from complete and prolonged occlusion of an epicardial coronary blood vessel and is defined based on ECG criteria....
متن کاملEffect of aspiration thrombectomy on microvascular obstruction in NSTEMI patients: the TATORT-NSTEMI trial.
BACKGROUND Aspiration thrombectomy in ST-segment elevation myocardial infarction is recommended by current guidelines based on several randomized trials. There are no trials assessing thrombectomy in non-ST-segment elevation myocardial infarction (NSTEMI) patients. OBJECTIVES The TATORT-NSTEMI (Thrombus Aspiration in Thrombus Containing Culprit Lesions in Non-ST-Elevation Myocardial Infarctio...
متن کاملEarly Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry
BACKGROUND P2Y12 antagonist therapy improves outcomes in acute myocardial infarction (MI) patients. Novel agents in this class are now available in the US. We studied the introduction of prasugrel into contemporary MI practice to understand the appropriateness of its use and assess for changes in antiplatelet management practices. METHODS AND RESULTS Using ACTION Registry-GWTG (Get-with-the-G...
متن کاملSTEMI and NSTEMI: the dangerous brothers.
With the creation of the NSTEMI as a new clinical entity, the need for data regarding prognosis and treatment options arose. By definition, STEMI and NSTEMI are only different with respect to the reflection of acute myocardial ischaemia and necrosis in the ECG. Although this difference may be triggered by the size of the infarcted area, it may also be only the location of the infarct—an occlude...
متن کاملAnother view on prasugrel.
Thromb Haemost 2009; 101: 12–13 The combination of aspirin with clopidogrel is currently the mainstay of antiplatelet therapy for patients with acute coronary syndromes (ACS) (1). While aspirin inhibits platelet thromboxane A2 production and platelet activation, clopidogrel inhibits adenosine diphosphate (ADP)-induced platelet activation by blocking the P2Y12 platelet receptor. When added to as...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2014
ISSN: 0735-1097
DOI: 10.1016/j.jacc.2014.09.064